National Institute of Allergy and Infectious Diseases
NIAID Home Health & Science Research Funding Research News & Events Labs at NIAID About NIAID

Respiratory Syncytial Virus
 Research
 Understanding
  Quick Facts
  Cause
  Transmission
  Symptoms
  Diagnosis
  Treatment
  Prevention


Respiratory Syncytial Virus

Prevention

Researchers have been working toward an respiratory syncytial virus (RSV) vaccine since the 1950s but no vaccine is yet licensed for use. The best way to prevent RSV is good hygiene and infection-control practices, such as washing your hands frequently with soap and water and avoiding sharing food, cups, or utensils with infected people. Using hand disinfectants will also kill the virus.

Infants at high risk for serious RSV infection or complications may be given Synagis (palivizumab), a therapy that has been shown to neutralize RSV, reduce infection rates, and reduce the severity of RSV infections. Synagis requires monthly, doctor-administered injections throughout the entire RSV season because each injection confers protection for just 30 days.

 Volunteer for Clinial Studies Button ClinicalTrials.gov has a full list of NIAID-funded clinical studies related to RSV.

See Also

Mouse Model Suggests New Treatment Strategy for Severe RSV


 Volunteer for Clinial Studies Button ClinicalTrials.gov has a full list of NIAID-funded clinical studies related to RSV.

See Also

Mouse Model Suggests New Treatment Strategy for Severe RSV